Aspartic acid

Generic Name: Aspartic acid

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₄H_₇NO_₄

CAS Number: 56-84-8

Unique Ingredient Identifier: 30KYC7MIAI

Background: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication: There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Therapies: Amino acid supplementation

Clinical Trials

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Regimen A
Drug: Regimen C
Drug: Regimen B
Drug: Regimen D

First Posted Date: 2010-11-01

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT01231568

Locations: 🇺🇸
GSK Investigational Site, Salt Lake City, Utah, United States

A Safety and Tolerability Study of Administration of PSD502

Phase 1

Completed

Conditions: Premature Ejaculation

Interventions: Drug: Intervention A
Drug: Intervention B
Drug: Intervention C
Drug: Intervention E
Drug: Intervention D

First Posted Date: 2010-08-17

Last Posted Date: 2016-08-10

Lead Sponsor: Plethora Solutions Ltd

Target Recruit Count: 21

Registration Number: NCT01183208

Locations: 🇬🇧
Bio-Kinetic Europe Limited, Belfast, United Kingdom

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G

First Posted Date: 2010-08-13

Last Posted Date: 2011-01-24

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT01181700

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Vitamin D Supplementation in Healthy Adolescents

Not Applicable

Completed

Conditions: Vitamin D Supplementation

Interventions: Drug: Supplemental Vitamin D

First Posted Date: 2010-05-20

Last Posted Date: 2018-06-04

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 56

Registration Number: NCT01126671

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

Fosamprenavir in Pts With Hepatic Impairment

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Intervention A Standard dose
Drug: Intervention B Reduced Dose
Drug: Intervention C
Drug: Intervention D
Drug: Intervention E

First Posted Date: 2010-01-22

Last Posted Date: 2013-05-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 167

Registration Number: NCT01054586

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Treatment E
Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D

First Posted Date: 2010-01-06

Last Posted Date: 2010-04-27

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT01043276

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment D
Drug: Treatment A
Drug: Treatment B
Drug: Treatment E
Drug: Treatment F
Drug: Treatment C

First Posted Date: 2009-07-27

Last Posted Date: 2013-03-19

Lead Sponsor: Tibotec BVBA

Target Recruit Count: 28

Registration Number: NCT00946842

A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D

First Posted Date: 2009-06-25

Last Posted Date: 2009-12-21

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00928278

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2009-02-27

Last Posted Date: 2020-04-07

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT00853008

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸
Clínica Teknon, Barcelona, Spain
🇪🇸
Hospital de Fuenlabrada, Madrid, Spain

and more 30 locations

Biomarkers in Schizophrenia

Phase 2

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: D Serine
Drug: Placebo

First Posted Date: 2009-01-06

Last Posted Date: 2017-08-02

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 16

Registration Number: NCT00817336

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy